Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215949 · ClinicalTrials.gov registry record · Phase 3
Zilucoplan for Severe gMG Exacerbations
A Phase 3 study of Generalized Myasthenia Gravis (gMG), sponsored by Miriam Freimer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07215949: Recruiting Phase 3 study of Generalized Myasthenia Gravis (gMG), sponsored by Miriam Freimer.
NCT07215949 is a Phase 3 study of Generalized Myasthenia Gravis (gMG) that is actively recruiting participants, run by Miriam Freimer. The registered enrollment target is 15 participants, below the 57-participant average among 4 other Generalized Myasthenia Gravis (gMG) trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215949, a Phase 3 study of Generalized Myasthenia Gravis (gMG), is actively recruiting participants, sponsored by Miriam Freimer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
Primary Outcome
The MG-ADL is an assessment that measures MG symptom severity. There are 8 items measured on a scale of 0-3 with 0 being the least severe. The total of the 8 items represents the MG-ADL score. The score can range from 0 (least severe) to 24 (most severe).
Conditions Studied
Interventions
- DRUG Zilucoplan®
Study Locations (1)
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2028-04-01 |
| Phase | Phase 3 |
What NCT07215949 shows while recruiting
NCT07215949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 57-participant average among 4 other Generalized Myasthenia Gravis (gMG) trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Generalized Myasthenia Gravis (gMG) appearing as the primary indexed condition, and to 1 intervention - of which Zilucoplan® is the first listed.
NCT07215949 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07215949 about?
NCT07215949 is a clinical study titled "Zilucoplan for Severe gMG Exacerbations". This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
What is the current status of trial NCT07215949?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2026-01-20. Estimated completion is 2028-04-01.
What conditions does trial NCT07215949 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis (gMG).
What interventions are being tested in trial NCT07215949?
The interventions under investigation include: Zilucoplan® (DRUG).
Who is sponsoring clinical trial NCT07215949?
This trial is sponsored by Miriam Freimer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215949 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis (gMG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
RECRUITING
-
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RECRUITING
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI